LINK . SPRINGER . COM {
}
Title:
Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion | Naunyn-Schmiedeberg's Archives of Pharmacology
Description:
It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Health & Fitness
- Social Networks
- TV
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We can't figure out the monetization strategy.
While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.
Keywords {🔍}
hmr, ischemia, article, hearts, reperfusion, rat, heart, min, privacy, cookies, function, content, effects, katp, rats, channels, flow, µmoll, information, publish, search, channel, cardiac, isolated, perfused, working, anesthetized, aortic, significant, access, data, log, journal, research, cardioselective, blocker, gögelein, ruetten, albus, lowflow, reduced, control, paced, period, potassium, discover, springer, optional, analysis, personal,
Topics {✒️}
month download article/chapter dg cardiovascular diseases pore-domain potassium katp channels article naunyn-schmiedeberg' global low-flow ischemia myocardial infarct size july 2001 volume 364 privacy choices/manage cookies heart muscle cells heart failure full article pdf endogenous cardioprotective mechanism arterial blood pressure reaching statistical significance murine disease models related subjects conditions privacy policy rat hearts vehicle-treated hearts channels heart rate low-flow ischemia accepting optional cookies european economic area aortic blood flow anesthetized rats subjected check access instant access journal finder publish article gögelein main content log cardiac function heinz gögelein statistically significant effects 30-min ischemic period anesthetized rats article log information privacy policy personal data coronary flow cardiodepressant effects books a article cite optional cookies manage preferences infarct size aortic flow ischemic period
Schema {🗺️}
WebPage:
mainEntity:
headline:Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion
description: It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
datePublished:
dateModified:
pageStart:33
pageEnd:41
sameAs:https://doi.org/10.1007/s002100000391
keywords:
KATP channel Heart Ischemia HMR 1098 HMR 1883 Rat Myocardial contractility
Pharmacology/Toxicology
Neurosciences
image:
isPartOf:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion
description: It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44±2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 µmol/l and 3 µmol/l HMR 1098 it had fallen to 29±7% (n=5, not significant) and 8±2% (n=12, P<0.05), respectively. Glibenclamide (3 µmol/l) reduced the aortic flow to 9.5±7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63±6 ms to 36±4 ms (n=10, P<0.05) within 4–6 min of low-flow ischemia. This shortening was completely prevented by 3 µmol/l HMR 1098 (60±5 ms before ischemia, 67±6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1098 (3 µmol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75±3%, HMR 1098: 72±2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
datePublished:
dateModified:
pageStart:33
pageEnd:41
sameAs:https://doi.org/10.1007/s002100000391
keywords:
KATP channel Heart Ischemia HMR 1098 HMR 1883 Rat Myocardial contractility
Pharmacology/Toxicology
Neurosciences
image:
isPartOf:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
type:
Periodical
PublicationVolume
publisher:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Naunyn-Schmiedeberg's Archives of Pharmacology
issn:
1432-1912
0028-1298
volumeNumber:364
Organization:
name:Springer-Verlag
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Heinz Gögelein
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Hartmut Ruetten
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Udo Albus
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Heinrich C. Englert
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
name:Andreas E. Busch
affiliation:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany
address:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
type:PostalAddress
type:Organization
PostalAddress:
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
name:Aventis Pharma Deutschland GmbH, DG Cardiovascular Diseases, Bldg. H 821, 65926 Frankfurt am Main, Germany,
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(33)
- What's the profit of https://www.springernature.com/gp/authors?
- What's https://link.springernature.com/home/'s gross income?
- How much does https://order.springer.com/public/cart rake in every month?
- What's the financial gain of https://submission.nature.com/new-submission/210/3?
- How much profit does https://www.springernature.com/gp/librarians/licensing/agc/journals make?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Heinz%20G%C3%B6gelein's total income per month
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Heinz%20G%C3%B6gelein%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
- What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hartmut%20Ruetten?
- How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hartmut%20Ruetten%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Udo%20Albus generate?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Udo%20Albus%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Heinrich%20C.%20Englert?
- How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Heinrich%20C.%20Englert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andreas%20E.%20Busch
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andreas%20E.%20Busch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- How much cash flow does https://s100.copyright.com/AppDispatchServlet?title=Effects%20of%20the%20cardioselective%20KATP%20channel%20blocker%20HMR%201098%20on%20cardiac%20function%20in%20isolated%20perfused%20working%20rat%20hearts%20and%20in%20anesthetized%20rats%20during%20ischemia%20and%20reperfusion&author=Heinz%20G%C3%B6gelein%20et%20al&contentID=10.1007%2Fs002100000391©right=Springer-Verlag&publication=0028-1298&publicationDate=2001-07&publisherName=SpringerNature&orderBeanReset=true have monthly?
- https://citation-needed.springer.com/v2/references/10.1007/s002100000391?format=refman&flavour=citation's total income per month
- What's the monthly money flow for https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
- https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research's total income per month
- How much revenue does https://www.springernature.com/gp/products bring in?
- How profitable is https://www.springernature.com/gp/librarians?
- Check the income stats for https://www.springernature.com/gp/societies
- What's the revenue for https://www.springernature.com/gp/partners?
- Discover the revenue of https://www.springer.com/
- How much money does https://www.nature.com/ make?
- Get to know what's the income of https://www.biomedcentral.com/
- What's the financial gain of https://www.palgrave.com/?
- How much profit does https://www.apress.com/ make?
- Revenue of https://www.springernature.com/gp/legal/ccpa
- How much profit does https://www.springernature.com/gp/info/accessibility make?
- Earnings of https://support.springernature.com/en/support/home
- https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations's revenue stream
- Discover the revenue of https://www.springernature.com/
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref